James C. Sacchettini

Active 1986–2026

195
Papers
33,719
Citations
104
h-index
176
i10-index

Citations

Citations per year for James C. Sacchettini1963: 1 citations1981: 1 citations1983: 1 citations1987: 11 citations1988: 15 citations1989: 25 citations1990: 26 citations1991: 23 citations1992: 50 citations1993: 60 citations1994: 84 citations1995: 93 citations1996: 123 citations1997: 107 citations1998: 149 citations1999: 153 citations2000: 195 citations2001: 202 citations2002: 268 citations2003: 243 citations2004: 255 citations2005: 264 citations2006: 268 citations2007: 282 citations2008: 289 citations2009: 392 citations2010: 450 citations2011: 365 citations2012: 389 citations2013: 404 citations2014: 417 citations2015: 338 citations2016: 326 citations2017: 310 citations2018: 287 citations2019: 866 citations2020: 832 citations2021: 734 citations2022: 596 citations2023: 457 citations2024: 631 citations2025: 301 citations2026: 14 citations1964–1980: no citations, so these years are not shown1982: no citations, so this year is not shown1984–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,280 citing papers, 32.8% of this breakdownChina: 1,108 citing papers, 8.5% of this breakdownUnited Kingdom: 1,067 citing papers, 8.2% of this breakdownGermany: 708 citing papers, 5.4% of this breakdownIndia: 524 citing papers, 4% of this breakdownFrance: 516 citing papers, 4% of this breakdownSwitzerland: 343 citing papers, 2.6% of this breakdownJapan: 316 citing papers, 2.4% of this breakdownCanada: 313 citing papers, 2.4% of this breakdownAustralia: 290 citing papers, 2.2% of this breakdownNetherlands: 282 citing papers, 2.2% of this breakdownItaly: 268 citing papers, 2.1% of this breakdown
0%32.8%Other 23.2%

Fields

  • Biochemistry, Genetics and Molecular Biology38.8%
  • Medicine36.3%
  • Immunology and Microbiology6.7%
  • Chemistry3.5%
  • Nursing2.6%
  • Materials Science2.5%
  • Other9.6%

Topics

  • Tuberculosis Research and Epidemiology7.7%
  • Mycobacterium research and diagnosis4.6%
  • RNA and protein synthesis mechanisms2.6%
  • Antibiotic Resistance in Bacteria2.3%
  • Computational Drug Discovery Methods2.2%
  • Biochemical and Molecular Research2%
  • Other78.6%

Coauthors

All papers

Open in search
  1. PHENIX: building new software for automated crystallographic structure determination

    Authors: , , , , , , , , , - Acta Crystallographica Section D Biological Crystallography 2002 cited by 4,410

  2. Elesclomol alleviates Menkes pathology and mortality by escorting Cu to cuproenzymes in mice

    Authors: , , , , , , , , , , , , , , , , - Science 2020 cited by 188

  3. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing

    Authors: , , , , , , , , - Nature Medicine 2013 cited by 547

  4. Crystal structure of a plant catechol oxidase containing a dicopper center

    Authors: , , , - Nature Structural Biology 1998 cited by 857

  5. Recent developments in thePHENIXsoftware for automated crystallographic structure determination

    Authors: , , , , , , , , , , , , , - Journal of Synchrotron Radiation 2003 cited by 394

  6. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase

    Authors: , , , , , , , , , - Nature 2000 cited by 1,368

  7. Tryptophan Biosynthesis Protects Mycobacteria from CD4 T-Cell-Mediated Killing

    Authors: , , , , , , , , , , , , - Cell 2013 cited by 371

  8. Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis

    Authors: , , , , - Science 1998 cited by 680

  9. Automated Structure Solution with the PHENIX Suite

    Authors: , , , , , , , , , , , , , - Methods in molecular biology 2008 cited by 562

  10. Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell 2017 cited by 185

  11. Mechanism of thioamide drug action against tuberculosis and leprosy

    Authors: , , , , , , - The Journal of Experimental Medicine 2007 cited by 295

  12. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Íñigo Angulo‐Barturen, Esther Pérez‐Herrán, Alfonso Mendoza, David Barros, S. Cusack, Jacob J. Plattner, M.R. Alley - Antimicrobial Agents and Chemotherapy 2016 cited by 121

  13. Mutations in fbiD ( Rv2983 ) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis

    Authors: , , , , , , , , - Antimicrobial Agents and Chemotherapy 2020 cited by 88

  14. Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

    Authors: , , , , , , , , , , , , - Nature Communications 2020 cited by 91

  15. The Tuberculosis Drug Accelerator at year 10: what have we learned?

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James C. Sacchettini, Dirk Schnappinger, Michael R. Schrimpf, Anna M. Upton, Peter Warner, Paul G. Wyatt, Ying Yuan - Nature Medicine 2021 cited by 62

  16. Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe

    Authors: , , , , , , , , - Nature Chemistry 2012 cited by 181

  17. TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities

    Authors: , , , , , , , , - PLoS Pathogens 2018 cited by 135

  18. Aspartate aminotransferase Rv3722c governs aspartate-dependent nitrogen metabolism in Mycobacterium tuberculosis

    Authors: , , , , , , , , , - Nature Communications 2020 cited by 73

  19. Structural anatomy of Protein Kinase C C1 domain interactions with diacylglycerol and other agonists

    Authors: , , , , , - Nature Communications 2022 cited by 53

  20. Catechol oxidase — structure and activity

    Authors: , , - Current Opinion in Structural Biology 1999 cited by 254

  21. Structure of the Mycobacterium tuberculosis d -Alanine: d -Alanine Ligase, a Target of the Antituberculosis Drug d -Cycloserine

    Authors: , , , , - Antimicrobial Agents and Chemotherapy 2010 cited by 146

  22. Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory T. Robertson, Chris Walpole, David J. Matthews, David Floyd, James C. Sacchettini, Kevin D. Read, Lourdes Encinas, Robert H. Bates, Simon R. Green, Paul G. Wyatt - Journal of Medicinal Chemistry 2021 cited by 35

  23. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection

    Authors: , , , , , , , , , , , - Nature Genetics 2011 cited by 467

  24. Altered NADH/NAD + Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria

    Authors: , , , , , , , , - Antimicrobial Agents and Chemotherapy 2005 cited by 283